Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Ambrx Biopharma Inc ADR
(NY:
AMAM
)
N/A
UNCHANGED
Last Price
Updated: 7:00 PM EDT, Mar 16, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ambrx Biopharma Inc ADR
< Previous
1
2
3
4
5
6
7
8
Next >
Ambrx Announces Encouraging Preliminary Safety and Efficacy Data Evaluating ARX788 in HER2 Positive Metastatic Breast Cancer Patients Who Progressed Following T-DM1 Treatment
December 09, 2022
From
Ambrx Biopharma Inc.
Via
Business Wire
Why Express Shares Are Trading Higher By 39%? Here Are 50 Stocks Moving In Thursday's Mid-Day Session
December 08, 2022
Gainers My Size, Inc. (NASDAQ: MYSZ) shares jumped 88% to $0.2839. My Size announced a 1-for-25 reverse stock split.
Via
Benzinga
Ambrx Biopharma Stops Working On Breast Cancer Candidate, Cites Competition As The Reason
October 19, 2022
Via
Benzinga
Ambrx Announces Abrupt Leadership Change, Discuses Pipeline Review
August 17, 2022
Via
Benzinga
Ambrx Biopharma's ARX788 Selected For Phase 2 Adaptive Breast Cancer Trial
April 26, 2022
Via
Benzinga
Why Summit Therapeutics Shares Are Trading Higher By Over 82%? Here Are 53 Stocks Moving In Tuesday's Mid-Day Session
December 06, 2022
Gainers Summit Therapeutics Inc. (NASDAQ: SMMT) shares surged 82.2% to $1.4299 after the company announced a definitive agreement of its partnership with Akeso to in-license its breakthrough bispecific...
Via
Benzinga
Why MEI Pharma Shares Are Trading Lower By Around 35%; Here Are 20 Stocks Moving Premarket
December 06, 2022
Gainers Starry Group Holdings, Inc. (NYSE: STRY) shares rose 43.5% to $0.2011 in pre-market trading after dipping more than 20% on Monday.
Via
Benzinga
Earnings Scheduled For April 26, 2022
April 26, 2022
Companies Reporting Before The Bell • First American Financial (NYSE:FAF) is estimated to report quarterly loss at $0.09 per share on revenue of $46.41 million.
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
December 05, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Friday
November 18, 2022
On Friday, 64 companies achieved new lows for the year.
Via
Benzinga
Week In Review: Insilico Signs Six-Drug Discovery Deal With Sanofi Worth Up To $1.2 Billion
November 12, 2022
Insilico Medicine signed a six-drug research collaboration with Sanofi that could be worth up to $1.2 billion. Insilico will receive up to $21.5 million in upfront and target nomination fees for each...
Via
Talk Markets
Ambrx Announces NovoCodex’s Dosing of First Patient with ARX305, Ambrx’s Investigational Antibody Drug Conjugate Targeting CD70
November 09, 2022
From
Ambrx
Via
Business Wire
Ambrx Biopharma Inc. Appoints Daniel O’Connor as Chief Executive Officer
November 01, 2022
From
Ambrx
Via
Business Wire
Stocks That Hit 52-Week Lows On Monday
September 12, 2022
During Monday's session, 38 stocks hit new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
October 25, 2022
On Tuesday, 120 companies set new 52-week lows.
Via
Benzinga
Why Minerva Neurosciences Shares Dipped By Around 70%; Here Are 90 Biggest Movers From Yesterday
October 18, 2022
Gainers Acorda Therapeutics, Inc. (NASDAQ: ACOR) surged 163.8% to close at $0.8970 on Monday after the company announced a $16.5 million award and royalty/supply relief in the AMPYRA arbitration case.
Via
Benzinga
Why Bank of America Shares Are Trading Higher? Here Are 66 Stocks Moving In Monday's Mid-Day Session
October 17, 2022
Gainers FedNat Holding Company (NASDAQ: FNHC) shares rose 78.9% to $0.93 after jumping 48% on Friday.
Via
Benzinga
Ambrx Biopharma Inc. Reports 1H 2022 Financial Results and Provides Corporate Update
August 29, 2022
From
Ambrx, Inc.
Via
Business Wire
Stocks That Hit 52-Week Lows On Thursday
August 18, 2022
During Thursday's trading, 62 companies set new 52-week lows.
Via
Benzinga
Ambrx Biopharma Appoints Kate Hermans as Interim CEO, Replacing Feng Tian
August 16, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Appoints Edward Hu and Kate Hermans to its Board of Directors
July 05, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Present at the H.C. Wainwright Preclinical Cancer Drug Discover Conference
June 28, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Appoints Janet Loesberg to Board of Directors
June 06, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Participate in Upcoming Investor Conferences
May 27, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Appoints Janice Lu, M.D., Ph.D., as Chief Medical Officer
May 17, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. to Present at Upcoming Investor Conferences
May 06, 2022
From
Ambrx, Inc.
Via
Business Wire
Ambrx Biopharma Inc. Announces Filing of Annual Report on Form 20-F
May 02, 2022
From
Ambrx Biopharma Inc.
Via
Business Wire
Ambrx Biopharma Inc. Reports Full Year 2021 Financial Results; Provides Corporate Update
April 26, 2022
From
Ambrx, Inc.
Via
Business Wire
The Daily Biotech Pulse: Protagonist's Ulcerative Colitis Study Disappoints, Gilead's Remdesivir Approved For Pediatric COVID-19 Patients, FDA Gives Nod To Gamida's Cell Therapy Trial, Fast Track Tag For Vascular Biogenics Ovarian Cancer Gene Therapy
April 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Ambrx Biopharma Inc. and Quantum Leap Healthcare Collaborative™ Announce the Inclusion of ARX788 in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
April 25, 2022
From
Ambrx, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.